rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    PMVP
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      PMV Pharmaceuticals Reports Third Quarter 2026 Financial Results and Corporate Highlights
      Nov 10Yahoo FinancePMVP
      PMV Pharma to present rezatapopt trial data at cancer symposium
      Nov 4Investing.comPMVP
      PMV Pharmaceuticals: Restoring Mutant P53 Could Create A Mispriced Cancer Opportunity
      Oct 7Seeking AlphaPMVP
      PMV Pharma appoints Matt Eckler to board of directors
      Oct 5Investing.comPMVP
      PMV Pharma at H.C. Wainwright: rezafapt nears pivotal test
      Sep 15Investing.comPMVP
      PMV Pharmaceuticals Appoints Philip Herman as Chief Commercial Officer

      Commercial leadership appointment supports launch preparation for rezatapopt Company planning NDA submission for accelerated approval of rezatapopt in patients with platinum-resistant/refractory ovarian cancer in first quarter of 2027 PRINCETON, N.J., Sept. 08, 2026 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (“PMV Pharma” or the “Company”; Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule therapies targeting p53, today announced the appoint

      Sep 8Yahoo FinancePMVP
      PMV Pharma Raises $50.8 Million to Fuel Cancer Drug Push

      PMV Pharmaceuticals Inc. (NASDAQ:PMVP) on Monday shared interim data from its Phase 2 PYNNACLE trial for rezatapopt, an investigational treatment for ovarian cancer.Based on this data, the company announced its plans to submit a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for accelerated approval of the drug.Efficacy HighlightsThe interim data, gathered up to May 14, 2026, focus on patients with platinum-resistant or refractory ovarian cancer bearing the TP53 Y220C

      Sep 1Yahoo FinancePMVP
      What's Going On With PMV Pharmaceuticals Stock Tuesday? - PMV Pharmaceuticals (NASDAQ:PMVP)
      Sep 1BenzingaPMVP
      PMV Pharma Announces Pricing of Oversubscribed $50 Million Public Offering of Securities
      Sep 1Yahoo FinancePMVP
      PMV Pharma Announces Proposed Public Offering of Securities

      PRINCETON, N.J., Aug. 31, 2026 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (“PMV Pharma” or the “Company”; Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule therapies targeting p53, announced today that it has commenced an underwritten public offering of shares of its common stock and accompanying warrants to purchase shares of its common stock and, in lieu of common stock, to certain investors, pre-funded warrants to purchase shares of its

      Aug 31Yahoo FinancePMVP
      PMV Pharmaceuticals Announces Updated Promising Rezatapopt Monotherapy Interim Ovarian Cancer Data From PYNNACLE Phase 2 Pivotal Trial

      46% ORR observed among 76 evaluable patients in the ovarian cancer cohort with a median duration of response of 10.0 monthsRecent FDA interaction supports NDA submission strategy for accelerated approval of rezatapopt for platinum-resistant/refractory ovarian cancer, with submission planned in first quarter of 2027PMV plans to provide an update on all PYNNACLE Phase 2 pivotal trial cohorts at a medical conference in fourth quarter of 2026 PRINCETON, N.J., Aug. 31, 2026 (GLOBE NEWSWIRE) -- PMV Ph

      Aug 31Yahoo FinancePMVP

      This is the newest page. Registered accounts read further back.